| Aug 23 |
Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
|
| Aug 22 |
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
|
| Aug 20 |
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
|
| Aug 14 |
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
|
| Aug 9 |
Oppenheimer sees Aquestive benefitting from FDA okay of rival drug
|
| Aug 8 |
Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 7 |
Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
| Aug 6 |
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
Aquestive Therapeutics: Q2 Earnings Snapshot
|
